Yoshioka Toshinori, Saitoh Akiyoshi
Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science.
Nihon Yakurigaku Zasshi. 2024;159(4):225-228. doi: 10.1254/fpj.24011.
Growing evidence has indicated that delta opioid receptor (DOP) agonists are potential psychotropic drugs such as for depression, anxiety, and PTSD. In rodent studies, we have also demonstrated that DOP agonists exhibit potent anxiolytic-like effects via the inhibition of the excitatory neuronal activity which projects to the amygdala from the prelimbic prefrontal cortex and facilitate extinction learning of contextual fear memory through PI3K-Akt signaling pathway in the infralimbic prefrontal cortex and MEK-ERK signaling pathway in the amygdala. In this article, we introduce the functional mechanisms underlying antidepressant-like effects and anti-stress effects of DOP agonists. Then, we employed a valid animal model of depression, chronic vicarious social defeat stress (cVSDS) mice, and investigated that the influence of DOP activation on pathopsychological factors in depression such as the adult hippocampal neurogenesis, hypothalamic-pituitary-adrenal (HPA) axis, and neuroinflammation. First, repeated administrations after the stress period to cVSDS mice with a selective DOP agonist, KNT-127, improved social interaction behaviors and reduced hyperactivation of the HPA axis without affecting hippocampal neurogenesis. Meanwhile, repeated KNT-127 administrations during the cVSDS period prevented the exacerbation of social interaction behaviors, dysregulation of the HPA axis, and excessive new-born neuronal cell death in the hippocampal dentate gyrus. Moreover, in both administration paradigms, KNT-127 suppressed microglial overactivation in the dentate gyrus of cVSDS mice. These results indicate that the underlying mechanism of DOP-induced antidepressant-like effects differ from those of conventional monoaminergic antidepressants. Furthermore, we propose that DOP agonists might have prophylactic effects as well as therapeutic effects on pathophysiological changes in depression.
越来越多的证据表明,δ阿片受体(DOP)激动剂是潜在的精神药物,如用于治疗抑郁症、焦虑症和创伤后应激障碍(PTSD)。在啮齿动物研究中,我们还证明,DOP激动剂通过抑制从前边缘前额叶皮质投射到杏仁核的兴奋性神经元活动,表现出强大的抗焦虑样作用,并通过内侧前额叶皮质中的PI3K-Akt信号通路和杏仁核中的MEK-ERK信号通路促进情境恐惧记忆的消退学习。在本文中,我们介绍了DOP激动剂抗抑郁样作用和抗应激作用的潜在功能机制。然后,我们使用了一种有效的抑郁症动物模型——慢性替代性社会挫败应激(cVSDS)小鼠,并研究了DOP激活对抑郁症病理心理因素的影响,如成年海马神经发生、下丘脑-垂体-肾上腺(HPA)轴和神经炎症。首先,在应激期后对cVSDS小鼠重复给予选择性DOP激动剂KNT-127,可改善社交互动行为,并降低HPA轴的过度激活,而不影响海马神经发生。同时,在cVSDS期间重复给予KNT-127可防止社交互动行为的恶化、HPA轴的失调以及海马齿状回中新生神经元细胞的过度死亡。此外,在两种给药模式中,KNT-127均抑制了cVSDS小鼠齿状回中的小胶质细胞过度激活。这些结果表明,DOP诱导的抗抑郁样作用的潜在机制与传统单胺能抗抑郁药不同。此外,我们提出DOP激动剂可能对抑郁症的病理生理变化具有预防作用和治疗作用。